Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, Transmedics Group Inc’s stock clocked out at $140.1, down -1.18% from its previous closing price of $141.77. In other words, the price has decreased by -$1.18 from its previous closing price. On the day, 0.82 million shares were traded. TMDX stock price reached its highest trading level at $143.23 during the session, while it also had its lowest trading level at $137.76.
Ratios:
To gain a deeper understanding of TMDX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.27 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 39.68. For the most recent quarter (mrq), Quick Ratio is recorded 7.13 and its Current Ratio is at 7.69. In the meantime, Its Debt-to-Equity ratio is 1.46 whereas as Long-Term Debt/Eq ratio is at 1.44.
On October 13, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $145.
On September 16, 2025, Evercore ISI started tracking the stock assigning a Outperform rating and target price of $155.Evercore ISI initiated its Outperform rating on September 16, 2025, with a $155 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 03 ’25 when DAVID WEILL bought 5,000 shares for $138.64 per share.
Ranganath Anil P. sold 3,000 shares of TMDX for $435,660 on Nov 25 ’25. The insider now owns 13,955 shares after completing the transaction at $145.22 per share. On Nov 25 ’25, another insider, ANIL P RANGANATH, who serves as the Officer of the company, bought 3,000 shares for $145.22 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TMDX now has a Market Capitalization of 4787823104 and an Enterprise Value of 4840997888. As of this moment, Transmedics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 56.59, and their Forward P/E ratio for the next fiscal year is 48.95. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.07. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.45 while its Price-to-Book (P/B) ratio in mrq is 13.47. Its current Enterprise Value per Revenue stands at 8.548 whereas that against EBITDA is 40.157.
Stock Price History:
The Beta on a monthly basis for TMDX is 2.00, which has changed by 1.1399245 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, TMDX has reached a high of $156.00, while it has fallen to a 52-week low of $55.00. The 50-Day Moving Average of the stock is 13.44%, while the 200-Day Moving Average is calculated to be 27.72%.
Shares Statistics:
It appears that TMDX traded 990.55K shares on average per day over the past three months and 1050030 shares per day over the past ten days. A total of 34.14M shares are outstanding, with a floating share count of 33.00M. Insiders hold about 3.43% of the company’s shares, while institutions hold 110.13% stake in the company. Shares short for TMDX as of 1763078400 were 6860927 with a Short Ratio of 6.93, compared to 1760486400 on 7971237. Therefore, it implies a Short% of Shares Outstanding of 6860927 and a Short% of Float of 34.43.
Earnings Estimates
A comprehensive evaluation of Transmedics Group Inc (TMDX) is underway, with the input of 8.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $0.71, with high estimates of $0.79 and low estimates of $0.55.
Analysts are recommending an EPS of between $2.82 and $2.38 for the fiscal current year, implying an average EPS of $2.58. EPS for the following year is $2.96, with 9.0 analysts recommending between $3.52 and $2.47.
Revenue Estimates
In. The current quarter, 10 analysts expect revenue to total $156.34M. It ranges from a high estimate of $160.1M to a low estimate of $155M. As of. The current estimate, Transmedics Group Inc’s year-ago sales were $121.62MFor the next quarter, 10 analysts are estimating revenue of $171.09M. There is a high estimate of $181.5M for the next quarter, whereas the lowest estimate is $163.4M.
A total of 13 analysts have provided revenue estimates for TMDX’s current fiscal year. The highest revenue estimate was $604.8M, while the lowest revenue estimate was $599M, resulting in an average revenue estimate of $601M. In the same quarter a year ago, actual revenue was $441.54MBased on 12 analysts’ estimates, the company’s revenue will be $724.94M in the next fiscal year. The high estimate is $753.9M and the low estimate is $686.8M.
